Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid. 1998

T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
PharmaBiotec Research Center, Department of Medicinal Chemistry, Royal Danish School of Pharmacy, 2 Universitetsparken, Copenhagen, Denmark.

(RS)-2-Amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid (Bu-HIBO, 6) has previously been shown to be an agonist at (RS)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptors and an inhibitor of CaCl2-dependent [3H]-(S)-glutamic acid binding (J. Med. Chem. 1992, 35, 3512-3519). To elucidate the pharmacological significance of this latter binding affinity, which is also shown by quisqualic acid (3) but not by AMPA, we have now resolved Bu-HIBO via diastereomeric salt formation using the diprotected Bu-HIBO derivative 11 and the enantiomers of 1-phenylethylamine (PEA). The absolute stereochemistry of (S)-Bu-HIBO (7) (ee = 99.0%) and (R)-Bu-HIBO (8) (ee > 99.6%) were established by an X-ray crystallographic analysis of compound 15, a salt of (R)-PEA, and diprotected 8. Circular dichroism spectra of 7 and 8 were recorded. Whereas 7 (IC50 = 0.64 microM) and 8 (IC50 = 0.57 microM) were equipotent as inhibitors of CaCl2-dependent [3H]-(S)-glutamic acid binding, neither enantiomer showed significant affinity for the synaptosomal (S)-glutamic acid uptake system(s). AMPA receptor affinity (IC50 = 0.48 microM) and agonism (EC50 = 17 microM) were shown to reside exclusively in the S-enantiomer, 7. Compounds 7 and 8 did not interact detectably with kainic acid or N-methyl-D-aspartic acid (NMDA) receptor sites. Neither 7 nor 8 affected the function of the metabotropic (S)-glutamic acid receptors mGlu2 and mGlu4a, expressed in CHO cells. Compound 8 was shown also to be inactive at mGlu1 alpha, whereas 7 was determined to be a moderately potent antagonist at mGlu1 alpha (Ki = 110 microM) and mGlu5a (Ki = 97 microM). Using the rat cortical wedge preparation, the AMPA receptor agonist effect of 7 was markedly potentiated by coadministration of 8 at 21 degrees C, but not at 2-4 degrees C. These observations together indicate that the potentiation of the AMPA receptor agonism of 7 by 8 is not mediated by metabotropic (S)-glutamate receptors but rather by the CaCl2-dependent (S)-glutamic acid binding system, which shows the characteristics of a transport mechanism. After intravenous administration in mice, 7 (ED50 = 44 mumol/kg) was slightly more potent than AMPA (1) (ED50 = 55 mumol/kg) and twice as potent as Bu-HIBO (6) (ED50 = 94 mumol/kg) as a convulsant, whereas 8 was inactive. After subcutaneous administration in mice, Bu-HIBO (ED50 = 110 mumol/kg) was twice as potent as AMPA (ED50 = 220 mumol/kg) as a convulsant. Since 7 and Bu-HIBO (EC50 = 37 microM) are much weaker than AMPA (EC50 = 3.5 microM) as AMPA receptor agonists in vitro, the presence of a butyl group in the molecules of Bu-HIBO and 7 seems to facilitate the penetration of these compounds through the blood-brain barrier.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D008297 Male Males
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002122 Calcium Chloride A salt used to replenish calcium levels, as an acid-producing diuretic, and as an antidote for magnesium poisoning. Calcium Chloride Dihydrate,Calcium Chloride, Anhydrous
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004594 Electrophysiology The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D000409 Alanine A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. Abufène,Alanine, L-Isomer,L-Alanine,Alanine, L Isomer,L Alanine,L-Isomer Alanine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
July 2002, Bioorganic & medicinal chemistry,
T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
January 1999, Chirality,
T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
November 2000, Chirality,
T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
January 2001, Chirality,
T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
April 1994, Journal of medicinal chemistry,
T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
March 2018, Journal of medicinal chemistry,
T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
November 2000, Journal of medicinal chemistry,
T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
May 2002, Chirality,
T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
October 1995, The Journal of pharmacology and experimental therapeutics,
T N Johansen, and B Ebert, and H Bräuner-Osborne, and M Didriksen, and I T Christensen, and K K Søby, and U Madsen, and P Krogsgaard-Larsen, and L Brehm
August 1996, Journal of medicinal chemistry,
Copied contents to your clipboard!